| 303 |
|
영단어 없음 |
최고관리자 |
2025-03-17 |
5 |
-
|
| 302 |
|
영단어 없음 |
최고관리자 |
2025-03-17 |
1 |
-
|
| 301 |
|
영단어 없음 |
최고관리자 |
2025-03-17 |
1 |
-
|
| 300 |
|
영단어 없음 |
최고관리자 |
2025-03-17 |
0 |
-
|
| 299 |
|
영단어없음 |
최고관리자 |
2025-03-17 |
7 |
-
|
| 298 |
|
stress test |
최고관리자 |
2025-03-17 |
1 |
-
|
| 297 |
|
subcommittee |
최고관리자 |
2025-03-17 |
0 |
-
|
| 296 |
|
sub-investigator |
최고관리자 |
2025-03-17 |
1 |
-
|
| 295 |
|
subject compensation guidelines |
최고관리자 |
2025-03-17 |
1 |
-
|
| 294 |
|
subject identification code |
최고관리자 |
2025-03-17 |
1 |
-
|
| 293 |
|
subject to administration |
최고관리자 |
2025-03-17 |
0 |
-
|
| 292 |
|
subject/trial subject |
최고관리자 |
2025-03-17 |
1 |
-
|
| 291 |
|
tailored review |
최고관리자 |
2025-03-17 |
0 |
-
|
| 290 |
|
technical documents of medical devices |
최고관리자 |
2025-03-17 |
0 |
-
|
| 289 |
|
testing methods and specifications |
최고관리자 |
2025-03-17 |
0 |
-
|
| 288 |
|
the Advanced Regenerative Medicine and Advanced Biological Products Policy Committee(Policy Committee) |
최고관리자 |
2025-03-17 |
1 |
-
|
| 287 |
|
The qualified person responsible for pharmacovigilance |
최고관리자 |
2025-03-17 |
0 |
-
|
| 286 |
|
tissue engineering products |
최고관리자 |
2025-03-17 |
1 |
-
|
| 285 |
|
tissue engineering therapy |
최고관리자 |
2025-03-17 |
0 |
-
|
| 284 |
|
traceability |
최고관리자 |
2025-03-17 |
0 |
-
|
| 283 |
|
treatment investigational new drug (treatment IND) |
최고관리자 |
2025-03-17 |
0 |
-
|
| 282 |
|
treatment protocols for advanced regenerative medicine |
최고관리자 |
2025-03-17 |
2 |
-
|
| 281 |
|
unexpected adverse drug reaction |
최고관리자 |
2025-03-17 |
0 |
-
|
| 280 |
|
unique identifying information |
최고관리자 |
2025-03-17 |
0 |
-
|
| 279 |
|
validation |
최고관리자 |
2025-03-17 |
1 |
-
|
| 278 |
|
validation master plan (VMP) |
최고관리자 |
2025-03-17 |
0 |
-
|
| 277 |
|
validation protocol |
최고관리자 |
2025-03-17 |
0 |
-
|
| 276 |
|
vulnerable subjects |
최고관리자 |
2025-03-17 |
0 |
-
|
| 275 |
|
well-being of the trial subjects |
최고관리자 |
2025-03-17 |
0 |
-
|
| 274 |
|
withdrawal |
최고관리자 |
2025-03-17 |
0 |
-
|
